What Is the Tenax Therapeutics, Inc. (TENX) Class Action Lawsuit About?
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tenax Therapeutics, Inc. (NASDAQ: TENX) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Tenax securities between November 13, 2023, and August 7, 2026, both dates inclusive (the “Class Period”).
Such investors are encouraged to join this case by visiting the firm’s website and providing their information.
What Does the Tenax Therapeutics, Inc. Securities Class Action Allege?
The Complaint alleges that throughout the Class Period, Defendants made statements that were materially false and/or misleading and/or failed to disclose that:
- the Company’s lead clinical program, TNX-103 was less effective than defendants had led investors to believe;
- accordingly, TNX-103’s overall clinical, regulatory, and commercial prospects were overstated; and
- as a result, the Company’s public statements were materially false and misleading at all relevant times.
How Is Tenax (NASDAQ: TENX) Stock Trading Today?
How Is BG&G Representing Investors in Securities Class Actions?
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”